tiprankstipranks
Trending News
More News >
ExpreS2ion Biotech Holding AB (SE:EXPRS2)
:EXPRS2
Sweden Market
Advertisement

ExpreS2ion Biotech Holding AB (EXPRS2) Stock Forecast & Price Target

Compare
0 Followers
See the Price Targets and Ratings of:

EXPRS2 Analyst Ratings

Hold
1Ratings
Hold
0 Buy
1 Hold
0 Sell
Based on 1 analysts giving stock ratings to
ExpreS2ion
Biotech Holding AB
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EXPRS2 Stock 12 Month Forecast

Average Price Target

kr22.45
▼(-6.07% Downside)
Based on 1 Wall Street analysts offering 12 month price targets for ExpreS2ion Biotech Holding AB in the last 3 months. The average price target is kr22.45 with a high forecast of kr22.50 and a low forecast of kr22.50. The average price target represents a -6.07% change from the last price of kr23.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"kr18","39":"kr39","23.25":"kr23.3","28.5":"kr28.5","33.75":"kr33.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.498240896294075,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr22.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.4495722341,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr22.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.498240896294075,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr22.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,23.25,28.5,33.75,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.05,24.853710838176468,24.657421676352936,24.461132514529403,24.26484335270587,24.068554190882338,23.872265029058802,23.67597586723527,23.479686705411737,23.283397543588205,23.087108381764672,22.89081921994114,22.694530058117607,{"y":22.498240896294075,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.05,24.84996709493077,24.64993418986154,24.449901284792308,24.24986837972308,24.049835474653847,23.849802569584615,23.649769664515386,23.449736759446154,23.24970385437692,23.049670949307693,22.84963804423846,22.649605139169232,{"y":22.4495722341,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.05,24.853710838176468,24.657421676352936,24.461132514529403,24.26484335270587,24.068554190882338,23.872265029058802,23.67597586723527,23.479686705411737,23.283397543588205,23.087108381764672,22.89081921994114,22.694530058117607,{"y":22.498240896294075,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":36,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":38.36,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":29.8,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.96,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.6,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":30.6,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.4,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.9,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.9,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.36,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.75,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.1,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":25.05,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Targetkr22.50Average Price Targetkr22.45Lowest Price Targetkr22.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on SE:EXPRS2
TR | OpenAI - 4o
TR | OpenAI - 4o
kr24kr22.5
Hold
-5.86%
Downside
Reiterated
08/16/25
AI Generated ArticleAI Generated Article
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on SE:EXPRS2
TR | OpenAI - 4o
TR | OpenAI - 4o
kr24kr22.5
Hold
-5.86%
Downside
Reiterated
08/16/25
AI Generated ArticleAI Generated Article
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

EXPRS2 Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
0
2
5
7
7
Sell
1
2
2
1
0
Strong Sell
0
0
0
0
0
total
1
4
7
8
7
In the current month, EXPRS2 has received 0 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. EXPRS2 average Analyst price target in the past 3 months is 22.45.
Each month's total comprises the sum of three months' worth of ratings.

EXPRS2 Financial Forecast

EXPRS2 Earnings Forecast

The previous quarter’s earnings for EXPRS2 were -kr4.30.
The previous quarter’s earnings for EXPRS2 were -kr4.30.

EXPRS2 Sales Forecast

The previous quarter’s earnings for EXPRS2 were kr1.33M.
The previous quarter’s earnings for EXPRS2 were kr1.33M.

EXPRS2 Stock Forecast FAQ

What is SE:EXPRS2’s average 12-month price target, according to analysts?
Based on analyst ratings, ExpreS2ion Biotech Holding AB’s 12-month average price target is 22.45.
    What is SE:EXPRS2’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for SE:EXPRS2, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is ExpreS2ion Biotech Holding AB a Buy, Sell or Hold?
        ExpreS2ion Biotech Holding AB has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
          What is ExpreS2ion Biotech Holding AB’s share price target?
          The average share price target for ExpreS2ion Biotech Holding AB is 22.45. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is kr22.50 ,and the lowest forecast is kr22.50. The average share price target represents -6.07% Decrease from the current price of kr23.9.
            What do analysts say about ExpreS2ion Biotech Holding AB?
            ExpreS2ion Biotech Holding AB’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
              How can I buy shares of ExpreS2ion Biotech Holding AB?
              To buy shares of SE:EXPRS2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis